The delicate conservation of the Pfizer-BioNTech vaccine against Covid-19, the first to be distributed, requires medical staff to manage the deliveries received with particular care.

The imminent arrival of other vaccines, meeting their own storage and injection constraints, should not make their task easier.

The vaccination campaign against Covid-19, launched Sunday in two establishments with the vaccine manufactured by Pfizer-BioNTech, requires complex logistics.

At this stage of distribution, France still depends solely on deliveries from Pfizer.

And faced with the difficulties of keeping the product, it has to practically manage the stocks bottle by bottle. 

Thus, we must at all costs avoid losses each time a vial - the equivalent of five doses - is opened.

These are therefore five vaccines that must be injected as quickly as possible.

If there are not enough volunteer patients to finish the vial, the facility's caregivers inherit the remaining doses.

This was the case on Sunday at René-Muret hospital in Sevran, where the first injections took place. 

>> LIVE -

 Coronavirus: follow the evolution of the situation Monday, December 28

Guarantee the access of the first vaccinated to the booster dose

It is also necessary to ensure that people vaccinated can benefit from the booster.

This second bite, which occurs 21 days later, is necessary to be immunized against the Covid-19 virus.

For this, France is stockpiling: when it receives a batch, half is sent for vaccination, the other half remains in a freezer pending the recall. 

This situation requires a lot of adaptation, recognizes Anne Jacolot, head of pharmacy at Sevran hospital.

"It will be a little tight organization and logistics. We are not always used to having all the constraints we have for this vaccine. It is a joint work between the doctor and the pharmacist" , she explains.

CORONAVIRUS ESSENTIALS

> Covid-19 vaccines: what do we really know about their side effects?

> What do we know about "long Covid", these patients who are going through hell?

> These three facets of the coronavirus that you may not have heard of

> When are we in contact?

And other questions that we ask ourselves every day

> Coronavirus: the 5 mistakes not to make with your mask

The highly anticipated AstraZneca vaccine, because it is easier to use

At the moment, there is only one vaccine.

The stock therefore remains easy to manage, but within a few weeks four other products should arrive in France, each with its conservation and injection constraints.

Moreover, the pharmaceutical group AstraZeneca declared Sunday to have found the winning formula to be as effective as its competitors of Pfizer-BioNTech and Moderna;

this vaccine is particularly expected because it is cheaper and also easier to store than the other two.